Opinion|Videos|November 27, 2023

Patient Case Presentation: A 69-Year-Old Man With NSCLC With EGFR Exon 20 Insertion Mutations

Author(s)Misako Nagasaka, MD, PhD, Sai-Hong Ou, MD, PhD, Janellen Smith, MD

Sai-Hong Ou, MD, PhD, and Janellen Smith, MD, discuss the management of a patient with non-small cell lung cancer and an EGFR exon 20 insertion mutation who experienced a rash while on treatment with amivantamab; they highlight the importance of continuous treatment and potential considerations for this patient group.

Episodes in this series

Misako Nagasaka, MD, PhD, and Kristen Neumann, DNP, FNP-C

EP. 1 Managing Treatment-Related Rashes in Patients With EGFR-Mutated NSCLC

Misako Nagasaka, MD, PhD, and Kristen Neumann, DNP, FNP-C

EP. 2 Managing Treatment-Related Diarrhea in Patients With EGFR-Mutated NSCLC

Misako Nagasaka, MD, PhD, and Kristen Neumann, DNP, FNP-C

EP. 3 Implementing Dose Reductions and Dose Holds in Patients With EGFR-Mutated NSCLC Receiving TKIs

Misako Nagasaka, MD, PhD, and Kristen Neumann, DNP, FNP-C

EP. 4 Multidisciplinary Management of Treatment-Related Adverse Events in Patients With EGFR-Mutated NSCLC

Misako Nagasaka, MD, PhD, and Kristen Neumann, DNP, FNP-C

EP. 5 Amivantamab for Patients With NSCLC and an EGFR Exon 20 Mutation

Misako Nagasaka, MD, PhD, and Kristen Neumann, DNP, FNP-C

EP. 6 Educating Patients and Clinical Staff on Infusion-Related Adverse Reactions Seen With Amivantamab in NSCLC With EGFR Exon 20 Mutations

Misako Nagasaka, MD, PhD, and Kristen Neumann, DNP, FNP-C

EP. 7 Future Perspectives in the Treatment and Management of Patients With EGFR-Mutated NSCLC

EP. 8 Approaches to Biomarker Testing in Non-Small Cell Lung Cancer (NSCLC)

EP. 8 Approaches to Biomarker Testing in Non-Small Cell Lung Cancer (NSCLC)

EP. 9 EGFR Mutations in Patients With NSCLC

EP. 9 EGFR Mutations in Patients With NSCLC

EP. 10 Adverse Effect Management in Non–Small Cell Lung Cancer Treatment

EP. 10 Adverse Effect Management in Non–Small Cell Lung Cancer Treatment

EP. 11 Patient Case Presentation: A 59-Year-Old Man With EGFR-Mutant NSCLC

EP. 11 Patient Case Presentation: A 59-Year-Old Man With EGFR-Mutant NSCLC

EP. 12 The Future of Treatment for EGFR TKI Resistance in EGFR-Mutant NSCLC

EP. 12 The Future of Treatment for EGFR TKI Resistance in EGFR-Mutant NSCLC

Next steps for research in lung cancer may include identifying how the gut microbiome impacts responses and adverse effects associated with treatment, says Misako Nagasaka, MD, PhD.

EP. 13 Multidisciplinary Care, Approval Updates, and Future Research in NSCLC

EP. 14 Treatment Approaches for Patients With EGFR-Mutant NSCLC

EP. 14 Treatment Approaches for Patients With EGFR-Mutant NSCLC

EP. 15 Common Adverse Events Seen With EGFR TKIs in EGFR-Mutant NSCLC

EP. 15 Common Adverse Events Seen With EGFR TKIs in EGFR-Mutant NSCLC

EP. 16 Approaches to Managing Patients With EGFR-Mutant NSCLC and EGFR TKI Resistance

EP. 16 Approaches to Managing Patients With EGFR-Mutant NSCLC and EGFR TKI Resistance

EP. 17 Patient Case Presentation: A 69-Year-Old Man With NSCLC With EGFR Exon 20 Insertion Mutations

EP. 17 Patient Case Presentation: A 69-Year-Old Man With NSCLC With EGFR Exon 20 Insertion Mutations

EP. 18 Management Strategies for Adverse Events Seen With Amivantamab in NSCLC With EGFR Exon 20 Insertion Mutations

EP. 18 Management Strategies for Adverse Events Seen With Amivantamab in NSCLC With EGFR Exon 20 Insertion Mutations

EP. 19 The Future of Treatment for NSCLC With EGFR Exon 20 Insertion Mutations

EP. 19 The Future of Treatment for NSCLC With EGFR Exon 20 Insertion Mutations

EP. 20 Unmet Needs and Future Perspectives in NSCLC Treatment

EP. 20 Unmet Needs and Future Perspectives in NSCLC Treatment

EP. 21 New Lung Cancer Treatment Options Combine Neoadjuvant and Adjuvant Therapies

EP. 21 New Lung Cancer Treatment Options Combine Neoadjuvant and Adjuvant Therapies

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Related to this article

At the BIG10 CRC Summit, Mingjia Li, MD, outlined how pre-operative hemoglobin may signal treatment response in resectable NSCLC.

October 20th, 2026

Monitoring Anemia and Optimizing Regimen Selection in Resectable NSCLC

At the BIG10 CRC Summit, Mingjia Li, MD, outlined how pre-operative hemoglobin may signal treatment response in resectable NSCLC.

Data from the real-world CEMI-LUNG evaluating cemiplimab in advanced NSCLC were consistent with reports from the EMPOWER-Lung1 study.

October 27th, 2026

Real-World Data on Cemiplimab Monotherapy Align With Prior NSCLC Studies

Data from the real-world CEMI-LUNG evaluating cemiplimab in advanced NSCLC were consistent with reports from the EMPOWER-Lung1 study.

Jesus Corral Jaime, MD, reviews real-world survival and response data for cemiplimab monotherapy from the CEMI-LUNG study.

October 26th, 2026

Cemiplimab Shows Real-World Efficacy in Advanced NSCLC Study

Jesus Corral Jaime, MD, reviews real-world survival and response data for cemiplimab monotherapy from the CEMI-LUNG study.

Calderasib Regimen Shows Meaningful Responses in Frontline KRAS G12C+ NSCLC

October 26th, 2026

Calderasib Regimen Shows Meaningful Responses in Frontline KRAS G12C+ NSCLC

Findings from the phase 1 KANDLELIT-001 study support further investigation of calderasib plus pembrolizumab in KRAS G12C-mutated metastatic NSCLC.

Initial data from the ROSETTA Lung-107 trial support further study of pumitamig in metastatic NSCLC previously managed with an immunotherapy-based regimen.

October 26th, 2026

Pumitamig Combo Yields Activity in Metastatic Non–Small Cell Lung Cancer

Initial data from the ROSETTA Lung-107 trial support further study of pumitamig in metastatic NSCLC previously managed with an immunotherapy-based regimen.

Based on data from the phase 3 SAFFRON trial, osimertinib plus savolitinib may establish a new global standard of care in this EGFR-mutated NSCLC population.

October 25th, 2026

Osimertinib/Savolitinib Improves Survival in MET-Altered EGFR-Mutant NSCLC

Based on data from the phase 3 SAFFRON trial, osimertinib plus savolitinib may establish a new global standard of care in this EGFR-mutated NSCLC population.

Data from the phase 3 Krascendo 1 trial support divarasib as a new standard in previously treated KRAS G12C–mutated non–small cell lung cancer.

October 25th, 2026

Divarasib Improves Survival vs Sotorasib or Adagrasib in KRAS G12C+ NSCLC

Data from the phase 3 Krascendo 1 trial support divarasib as a new standard in previously treated KRAS G12C–mutated non–small cell lung cancer.

Pope Leo XIV’s lung adenocarcinoma diagnosis may increase awareness and combat stigma surrounding lung cancer screening.

October 22nd, 2026

What Pope Leo XIV’s Lung Cancer Diagnosis Could Mean for Stigma, Nihilism

Pope Leo XIV’s lung adenocarcinoma diagnosis may increase awareness and combat stigma surrounding lung cancer screening.

Trending on CancerNetwork

Sac-TMT Improves Survival vs Chemotherapy in Pretreated Endometrial Cancer

Cemiplimab Shows Real-World Efficacy in Advanced NSCLC Study

Pembrolizumab Improves PFS Over Chemo in dMMR Endometrial Cancer

Calderasib Regimen Shows Meaningful Responses in Frontline KRAS G12C+ NSCLC

Could Oral Vitamin C Confer OS Benefit in CCUS and Lower-Risk MDS?